Clinical Trial Update: Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

View source ↗

Summary

The compassionate use program for BRAF mutation-positive melanoma patients after surgical resection is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma, Adjuvant | Status: NO_LONGER_AVAILABLE